EDAP VS CYBN Stock Comparison

Performance

EDAP
10/100

EDAP returned -58.33% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

CYBN
100/100

CYBN returned -1.50% in the last 12 months. Based on SPY's performance of -13.84%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

EDAP
75/100

2 analysts offer 12-month price targets for EDAP. Together, they have an average target of 0, the most optimistic target put EDAP at 0 within 12-months and the most pessimistic has EDAP at 0.

CYBN

"Analyst Price Targets" not found for CYBN

Sentiment

EDAP
70/100

EDAP had a bullish sentiment score of 69.60% across Twitter and StockTwits over the last 12 months. It had an average of 2.38 posts, 2.46 comments, and 1.77 likes per day.

CYBN

"Sentiment" not found for CYBN

Technicals

EDAP
14/100

EDAP receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

CYBN
39/100

CYBN receives a 39 of 100 based on 14 indicators. 5 are bullish, 8 are bearish.

Earnings

EDAP
10/100

EDAP has missed earnings 9 times in the last 20 quarters.

CYBN
10/100

CYBN has missed earnings 5 times in the last 20 quarters.

Profit

EDAP
42/100

Out of the last 20 quarters, EDAP has had 11 profitable quarters and has increased their profits year over year on 4 of them.

CYBN
10/100

Out of the last 9 quarters, CYBN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

EDAP
53/100

EDAP has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

CYBN
39/100

CYBN has had a lower than average amount of volatility over the last 12 months giving it a score of 38 of 100.

All score calculations are broken down here to help you make more informed investing decisions

EDAP TMS SA Summary

Nasdaq / EDAP

Healthcare

Medical - Devices

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Cybin Inc. Summary

Healthcare

Biotechnology

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Power up your portfolio